Robert Zaczek new CSO at NeurOp
This article was originally published in Scrip
Executive Summary
Atlanta-based biopharmaceutical company NeurOp, which specialises in developing new medicines for central nervous system disorders, has appointed Dr Robert Zaczek chief scientific officer. Dr Zaczek most recently served as executive director of psychiatry drug discovery at Bristol-Myers Squibb, during which time he headed the joint research team that currently collaborates with NeurOp on its depression and neuropathic pain programmes.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.